Filtered By:
Condition: Pain
Cancer: Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Diagnostic reference levels and median doses for common clinical indications of CT: findings from an international registry
ConclusionsDRLs for CTDIvol and DLP for EUCLID clinical indications from diverse organizations were established and can contribute to dose optimization. These values were usually significantly higher in the US than in Europe.Key Points•Registry data were used to create benchmarks for 10 common indications for CT identified by the European Society of Radiology.•Observed US radiation doses were higher than European for 9 of 10 indications (except chronic sinusitis).•The presented diagnostic reference levels and median doses highlight potentially unnecessary variation in radiation dose.
Source: European Radiology - October 13, 2021 Category: Radiology Source Type: research
Cerebellar Stroke and Leptomeningeal Carcinomatosis following Cement Leakage into the Vertebral Artery during Cervical Vertebroplasty
This report describes an unusual vertebral artery cement embolization during C3 transpedicular vertebroplasty performed under computed tomography (CT) guidance and fluoroscopy. The Institutional Review Board approved this case report, and the patient ’s consent for publication was obtained. A 54-year-old woman with an invasive lobular breast carcinoma suffered from cervical pain. A CT scan showed spinal osteolytic lesions. A thoracic vertebral biopsy confirmed the diagnosis of breast cancer metastasis.
Source: Journal of Vascular and Interventional Radiology : JVIR - September 28, 2021 Category: Radiology Authors: Fabrice Bing, Jad Dandache, Luce Mettey, Wilfried Vadot, Laetitia Stefani Tags: Letter to the Editor Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
CT diagnostic reference levels based on clinical indications: results of a large-scale European survey
ConclusionsThis is the first study reporting on feasibility of establishing CT DRLs based on CI using European data. Resulting values will serve as a baseline for comparison with local radiological practice, national authorities when DRLs are set/updated, or as a guideline for local DRL establishment.Key Points•First study reporting on the feasibility of establishing CT diagnostic reference levels based on clinical indication using data collected across Europe.•Only one-fourth of the hospitals had CT machines less than 5 years old.•Large dose variations were observed among hospitals and CT protocols were quite differ...
Source: European Radiology - January 15, 2021 Category: Radiology Source Type: research
Cardiac Transplantation for Cancer Involving the Heart
Cardiac Cancer (CC) that arises from or involves the heart can present as heart failure, chest pain, stroke or another thromboembolic event. Although patients with CC have limited treatment options, in other organ cancers such as hepatocellular carcinoma, liver transplant improves 5-year overall survival in carefully selected patients1. For CC, however, the benefit of replacing the cancerous heart is uncertain because one-year survival is generally estimated around 50% after this rare operation.
Source: The Journal of Heart and Lung Transplantation - May 23, 2020 Category: Transplant Surgery Authors: Matthew Wingo, Andreas R. de Biasi, Yasuhiro Shudo, Vijaya Bharathi, Anthony Blackburn, Mario Gaudino, Leonard N. Girardi, Y. Joseph Woo Tags: Research Correspondence Source Type: research
439OA first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
ConclusionsNP137 was well-tolerated, with mild to moderate IRR as the most frequent treatment-related AEs and showed encouraging signs of clinical activity. Updated data will be presented at the meeting.Clinical trial identificationNCT02977195.Legal entity responsible for the studyCentre L éon Bérard.FundingNetris Pharma.DisclosureP. Cassier: Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Research grant / Funding (institution), Travel / Accommodation /...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion
The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research
Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives
Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions.
Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.
PMID: 29921512 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM Tags: Gynecol Oncol Source Type: research
Successful deep brain stimulation for central post-stroke pain and dystonia in a single operation
Conclusions Deep brain stimulation targeting multiple brain networks in one operation is feasible and safe. Deep brain stimulation may be considered in some refractory cases of central post-stroke pain; however, it requires meticulous programming.
Source: Journal of Clinical Neuroscience - March 16, 2018 Category: Neuroscience Source Type: research
A rare cause of headache-the importance of a tissue diagnosis and perseverance
A 64 year old diabetic hypertensive milkman presented in September 2011 with 4 months progressive constant right frontotemporal retro–orbital pain. It was worse at night affecting sleep with slight right field blurring and later vomiting. Full examination including blood pressure was normal with acuities 6/9. Tension type headache was considered. Initial brain CT was reported as normal. With concern about giant cell arteritis steroids were trialled although ESR was 8 and CRP 25 with no other clinical features: pain reduction was short–lived and temporal artery biopsy negative. Symptoms worsened despite analgesi...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Defty, H., Cavazza, A., Warner, G. Tags: Immunology (including allergy), Cranial nerves, Headache (including migraine), Neurooncology, Pain (neurology), Stroke, Hypertension, CNS cancer, Ophthalmology, Pain (palliative care), Anxiety disorders (including OCD and PTSD), Radiology, Disability, Dru Source Type: research
Preparation of well-defined ibuprofen prodrug micelles by RAFT polymerization.
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat acute pain, fever and inflammation and are being explored in a new indication in cancer. Side effects associated with long-term use of NSAIDs such as gastrointestinal damage and elevated risk of stroke, however, can limit their use and exploration in new indications. Here we report a facile method to prepare well-defined amphiphilic diblock copolymer NSAID prodrugs by direct reversible addition fragmentation transfer (RAFT) polymerization of the acrylamide derivative of ibuprofen (IBU), a widely used NSAID. The synthesis and self-as...
Source: Biomacromolecules - August 12, 2013 Category: Biochemistry Authors: Hasegawa U, van der Vlies AJ, Wandrey C, Hubbell JA Tags: Biomacromolecules Source Type: research
Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease.
They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older.
The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news
